LOGIN  |  REGISTER
Chimerix
Recursion

Streamline Health Solutions Expands RevID™ Agreement With 400-Bed Children’s Health System

July 16, 2024 | Last Trade: US$3.61 0.26 -6.72

ATLANTA, July 16, 2024 (GLOBE NEWSWIRE) --  Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its contract for the use of RevID with a 425-bed, Oracle-EHR based health system and extended the term for an additional 5 years.

Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation accelerates cash flow by ensuring that providers can accurately capture, bill and ultimately be paid for all the care they provide.

“We are pleased with the continued trust our client places in our products and our team,” stated Ben Stilwill, President and Chief Executive Officer, Streamline. “We look forward to supporting their quest to be accurately paid for all of the care they’ve provided and sharing their experience with future clients.”

About Streamline Health

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net

C4 Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page